AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
PTC Therapeutics, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SNNC86
60.59▼ 2.45 (-3.89%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
63.04
Day's Range
59.97 – 63.49
52-Week Range
58.80 – 90.87
Volume
674.1K
Avg Volume
1.2M
Share Statistics
Shares Outstanding
Employees
991
Exchange
XNAS
Listed
2013-06-20
Share count as of July 29, 2026

PTC Therapeutics, Inc. (PTCT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about PTC Therapeutics, Inc. (PTCT)
What is PTC Therapeutics, Inc.'s Market Cap?
PTC Therapeutics, Inc.'s Market Cap is $5.1B, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s Enterprise Value?
PTC Therapeutics, Inc.'s Enterprise Value is $3.5B, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s Price / Sales?
PTC Therapeutics, Inc.'s Price / Sales is 5.0×, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s EV / Revenue?
PTC Therapeutics, Inc.'s EV / Revenue is 3.4×, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s EV / EBITDA?
PTC Therapeutics, Inc.'s EV / EBITDA is 19.1×, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s Revenue (TTM)?
PTC Therapeutics, Inc.'s Revenue (TTM) is $1.0B, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s Net Income (TTM)?
PTC Therapeutics, Inc.'s Net Income (TTM) is -$38.4M, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s EBITDA?
PTC Therapeutics, Inc.'s EBITDA is $180.9M, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s Diluted EPS (TTM)?
PTC Therapeutics, Inc.'s Diluted EPS (TTM) is -0.46, based on as-reported figures from SEC (XBRL) filings.
What is PTC Therapeutics, Inc.'s EBITDA Margin?
PTC Therapeutics, Inc.'s EBITDA Margin is 17.9%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PTCTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+101.5%-76.8%-22.7%+7.2%
Operating expenses:
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets
Amortization of acquired intangible assets
Research and development
Selling, general and administrative
Change in the fair value of contingent consideration——
Tangible asset impairment and losses on transactions, net
Total operating expenses
% of revenue58.7%83.5%143.3%98.6%
Income (loss) from operations
% of revenue41.3%16.5%-43.3%1.4%
Interest expense, net
Other expense, net
Income (loss) before income tax (expense) benefit
Income tax (expense) benefit
Net income (loss) attributable to common stockholders
% of revenue23.2%-1.0%-82.0%7.5%
Basic (in dollars per share)
Diluted (in dollars per share)